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Abstract
Objective To determine the independent associations of antihypertensive
drugs with the risk of incident gout among people with hypertension.
Design Nested case-control study.
Setting UK general practice database, 2000-7.
Participants All incident cases of gout (n=24 768) among adults aged
20-79 and a random sample of 50 000 matched controls.
Main outcome measure Relative risk of incident gout associated with
use of antihypertensive drugs.
Results After adjusting for age, sex, body mass index, visits to the
general practitioner, alcohol intake, and pertinent drugs and
comorbidities, the multivariate relative risks of incident gout associated
with current use of antihypertensive drugs among those with hypertension
(n=29 138) were 0.87 (95% confidence interval 0.82 to 0.93) for calcium
channel blockers, 0.81 (0.70 to 0.94) for losartan, 2.36 (2.21 to 2.52) for
diuretics, 1.48 (1.40 to 1.57) for β blockers, 1.24 (1.17 to 1.32) for
angiotensin converting enzyme inhibitors, and 1.29 (1.16 to 1.43) for
non-losartan angiotensin II receptor blockers. Similar results were
obtained among those without hypertension. The multivariate relative
risks for the duration of use of calcium channel blockers among those
with hypertension were 1.02 for less than one year, 0.88 for 1-1.9 years,
and 0.75 for two or more years and for use of losartan they were 0.98,
0.87, and 0.71, respectively (both P<0.05 for trend).
Conclusions Compatible with their urate lowering properties, calcium
channel blockers and losartan are associated with a lower risk of incident
gout among people with hypertension. By contrast, diuretics, β blockers,
angiotensin converting enzyme inhibitors, and non-losartan angiotensin
II receptor blockers are associated with an increased risk of gout.
Introduction
Hypertensionisoneofthemostcommoncomorbiditiesofgout.
According to the latest estimates from the US National Health
and Nutrition Examination Survey (2007-8), 74% of patients
with gout have hypertension,
1 which corresponds to 6.1 million
adults in the United States alone. This substantial burden of
comorbidity possibly stems from copathogenesis of the two
conditionsorrenalchangesinhypertensionleadingtodecreased
urate excretion. Studies have shown that the presence of
hypertensionisindependentlyassociatedwiththeriskofincident
gout
2 through reduced renal blood flow with increased renal
and systemic vascular resistance and decreased renal excretion
of urate.
3-6
Certainantihypertensivedrugsalsoincreasethelevelsofserum
uric acid and thus may contribute to the risk of gout. For
example, in addition to the well known entities of diuretic
induced hyperuricaemia and gout,
3 7 8 the use of β blockers has
been shown to increase levels of serum uric acid in short-term
trials.
8 9 However, calcium channel blockers and losartan have
been found to lower serum uric acid levels,
10-16 carrying the
potential to lower the risk of gout. To date, however, no study
has investigated the relation between various antihypertensive
agentsandtheriskofgout.Toaddresstheseissues,weanalysed
a cohort of 24 768 people with newly diagnosed gout and 50
000 matched controls from the health improvement network
database.
Methods
Study population
The health improvement network database contains
computerised medical records entered by general practitioners
in the United Kingdom.
17 Data on about four million patients
are systematically recorded and sent anonymously to the
database. Patients included in the database are representative
of the UK population for age, sex, and geographical region.
17
The health improvement network collects and organises this
information for the purpose of research projects. The
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Research
RESEARCHcomputerised information includes personal characteristics of
the patients, details of visits to general practitioners, diagnoses
from referrals to specialists and hospital admissions, results of
laboratory tests, and a free text section (information available
on request). Diagnoses are recorded using READ codes.
18 19
Prescriptions issued by primary care providers are recorded
automaticallyinthedatabase;drugsarecodedusingtheMultilex
classification (www.firstdatabank.co.uk/8/multilex-drug-data-
file). An additional requirement for participating practices is to
record the indication for new courses of treatment. The validity
ofthedatabaseforpharmacoepidemiologicalresearchhasbeen
shown.
20
We carried out a nested case-control study using data from the
health improvement network database between January 2000
and December 2007. The source population included all adults
aged 20-89 with permanent registration status or who had died
in the last update of the database. Study cohort members were
required to have been enrolled with their general practitioner
for two or more years, had at least one visit to their general
practitioner, and had at least one prescription in the two years
before entering the study. The start date corresponded to the
date when all of these eligibility criteria had been met. People
had to be free of gout and cancer before entering the study. All
participantsinthestudycohortwerefollowedupandcontributed
person time from their respective start date until the earliest of
oneofthefollowingendpoints:detectionofgout,90thbirthday,
death, or end of study period, whichever came first. The final
cohort encompassed 1 775 505 people followed for an average
of 5.2 years.
Ascertainment of gout
From an automatic search using READ codes we identified all
people with a first ever diagnosis of gout recorded by a general
practitioner. The date of gout onset (index date) was defined as
the date of either the first diagnosis of gout or the first anti-gout
treatment (allopurinol, colchicine, or uricosuric drugs),
whichever came first, among those with a diagnosis of gout.
We considered incident cases as those who had an index date
(gout onset) occurring after the date of entry to the study cohort
(n=24 768).
To evaluate the robustness of gout ascertainment, we carried
out a sensitivity analysis restricting people with gout to those
receivinganti-gouttreatment.Tothisendweusedthefollowing
operational definition: identified within 90 days of a first ever
diagnosis of gout (index date), any anti-gout treatment
(colchicine, probenecid, or uricosuric drugs), or a prescription
of a non-steroidal anti-inflammatory drug on the same index
date. A similar case definition of gout has been shown to have
a validity of 90% in the general practice research database.
21 22
Control sampling
From the same study cohort where we ascertained gout cases
we sampled 50 000 controls that were frequency matched on
age, sex, and calendar year. We applied the same exclusion
criteria to controls as to cases. This was done by generating at
random a date encompassed within the study period for each
member of the study population. If the random date for a study
member was included in his or her eligible person time
(follow-up period), we chose that person as an eligible control
and we used the random date as their index date.
Use of antihypertensive drugs
We evaluated the potential impact of antihypertensive drugs by
class: diuretics, β blockers, calcium channel blockers,
angiotensin converting enzyme inhibitors, losartan, and
non-losartan angiotensin II receptor blockers. Since previous
literaturehassuggestedthat,unlikeotherangiotensinIIreceptor
blockers, losartan shows urate lowering properties,
12 13 we
evaluateditsindividualeffectseparatelyfromotherangiotensin
IIreceptorblockers.Weclassifieduseofantihypertensivedrugs
into four mutually exclusive usage groups: current use (the
supplyofthemostrecentprescriptionlasteduntiltheindexdate
or ended in the 30 days before that date), recent use (the supply
of the most recent prescription ended between 31 and 365 days
before the index date), past use (the supply of the most recent
prescription ended more than 365 days before the index date),
and never use (no recorded use at any time before the index
date).Durationoftreatmentwascalculatedamongcurrentusers
of drugs, which we computed by summing the time of
consecutive prescriptions (allowing for an maximum interval
of 60 days between the end of one prescription and the start of
another).Toanalysepotentialdoseeffectsweusedinformation
on dose from the British National Formulary (http://bnf.org/
bnf/index.htm)andclassifieddoseofantihypertensivedruginto
three groups: medium or low (recommended starting doses or
lower), high (higher than recommended starting doses), and
unknown.
Covariate assessment
Fromthedatabasewecollecteddataonpersonalcharacteristics
and lifestyle factors such as alcohol use, smoking, and body
mass index, as well as comorbidities such as ischaemic heart
disease, hypertension, hyperlipidaemia, renal failure, and heart
failure before the index date. The presence of these
comorbidities was defined using READ codes for diagnosis as
recorded by the general practitioners. We also ascertained the
numbers of visits to a general practitioner, referrals, and
admission to hospital in the year before the index date.
Statistical analysis
Using unconditional logistic regression we estimated the odds
ratios and 95% confidence intervals for gout associated with
use of calcium channel blockers, losartan, and other
antihypertensive drug classes. Our multivariate analyses were
adjustedforthefrequencymatchedvariables,visitstoageneral
practitioner, and the covariates of body mass index (five
categories), alcohol use (six categories), smoking (four
categories), ischaemic heart disease, hypertension,
hyperlipidaemia,andrenalfailure.Toestimatetheindependent
impact of each drug class, even among those who used a
combinationofantihypertensivedrugclasses,wesimultaneously
adjustedtheseregressionmodelsforeachantihypertensivedrug
class. In addition we examined associations with relatively
common combinations of antihypertensive treatment in our
study population (>3% prevalence of use among users of
antihypertensives)comparedwithnoantihypertensiveusewhile
adjustingforothercombinationsandthesamesetofcovariates.
Under our study design the odds ratio is an unbiased estimator
of the incidence rate ratio and we have reported odds ratio
estimates as relative risks throughout this paper. We calculated
absolute risk differences by applying these relative risks to the
incidence rates of gout derived from our underlying cohort. We
carried out stratified analyses by presence of hypertension to
explore potential differences in the impact of antihypertensive
drugs depending on the presence of hypertension and to help
isolatetheimpactofparticularantihypertensives.Wetestedthe
significance of the interaction with a likelihood ratio test by
introducingtheinteractiontermtoourfinalmodelwiththemain
terms.
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The study included 24 768 patients with newly diagnosed gout
and 50 000 controls; table 1⇓ shows their characteristics,
stratified by the presence of hypertension. In both groups gout
was associated with an increased number of visits to a general
practitioner, alcohol use, adiposity, ischaemic heart disease,
hyperlipidaemia, and renal failure. In total, 12 858 (51.9%)
patients with gout had a recorded diagnosis of hypertension
before the diagnosis of gout. After adjusting for age, sex,
calendar year, and visits to a general practitioner, the relative
risk for incident gout among those with hypertension was 1.99
(95% confidence interval 1.92 to 2.06) compared with those
without hypertension. After further adjustment for other
covariates, this relative risk was attenuated but remained
significant (1.75, 1.69 to 1.82).
Comparedwithnouseofcalciumchannelblockers,currentuse
among people with hypertension was associated with a lower
risk of developing gout (table 2⇓). After adjusting for age, sex,
calendar year, and visits to a general practitioner, the relative
risk for gout among those currently using calcium channel
blockers was 0.95 (0.90 to 1.00). After adjusting for other
covariates and other antihypertensive drugs, the multivariate
relative risk was 0.87 (0.82 to 0.93). (The corresponding
absoluteriskdifferencewas60casesper100000personyears.)
The multivariate relative risks for individual calcium channel
blockers were 0.79 (0.73 to 0.86) for amlodipine, 0.87 (0.78 to
0.97) for nifedipine, and 0.86 (0.75 to 0.99) for diltiazem. The
associations were similar among people without hypertension
(P=0.17 for interaction, table 2). The multivariate relative risks
forcalciumchannelblockersaccordingtodurationofuseamong
those with hypertension were 1.04 for less than one year, 0.89
for1-1.9years,and0.77fortwoormoreyears(95%confidence
interval 0.71 to 0.83, P<0.001 for trend, table 3⇓). The inverse
association was stronger with high dose use of calcium channel
blockersthanwithmediumorlowdoseuse(multivariaterelative
risk 0.80 v 0.90; P=0.02, table 4⇓).
Similarly,currentuseoflosartanamongthosewithhypertension
wasassociatedwithalowerriskofdevelopinggout(multivariate
relative risk compared with no use of losartan was 0.81, 0.70
to 0.94, table 2). (The corresponding absolute risk difference
was 86 cases per 100 000 person years.) The association was
not significantly different among those without hypertension
(P=0.20 for interaction), but the frequency of losartan use in
the group without hypertension was low (table 2). The
multivariate relative risks according to duration of use among
those with hypertension were 0.97 for less than one year, 0.86
for 1-1.9 years, and 0.70 for two or more years (0.57 to 0.86,
P=0.02 for trend, table 3). The inverse association tended to be
stronger with high dose use of losartan than with medium or
low dose use (multivariate relative risk 0.66 v 0.88; P=0.06,
table 4).
In contrast, current use of diuretics, β blockers, angiotensin
converting enzyme inhibitors, and non-losartan angiotensin II
receptor blockers among those with hypertension were all
associatedwithanincreasedriskofdevelopinggout.Compared
with no use of diuretics, current use was associated with the
greatest multivariate relative risk (2.36, 2.21 to 2.52). The
corresponding multivariate relative risks of incident gout were
1.48 (1.40 to 1.57) for β blockers, 1.24 (1.17 to 1.32) for
angiotensin converting enzyme inhibitors, and 1.29 (1.16 to
1.43) for non-losartan angiotensin II receptor blockers (table
2).(Therespectiveabsoluteriskdifferenceswere572,218,109,
and 132 cases per 100 000 person years.) These multivariate
relative risks tended to increase with increasing duration of use
among those with hypertension (P<0.05 for trend) except for β
blockersandnon-losartanangiotensinIIreceptorblockers(table
3). These associations tended to be stronger with higher doses
than with medium or low doses, except for angiotensin
converting enzyme inhibitors (table 4). Overall, these relative
risks tended to be similar among those without hypertension
exceptfortherelationbetweendurationofuseandnon-losartan
angiotensinIIreceptorblockers.Notably,thefrequencyofsuch
use in this group was low.
In our sensitivity analysis, restricting gout cases to those
receiving anti-gout treatment (n=19 749), the multivariate
relative risks of incident gout associated with current use of
antihypertensive drugs among those with hypertension (n=10
195)were0.87(0.82to0.93)forcalciumchannelblockers,0.78
(0.67to0.92)forlosartan,2.35(2.19to2.53)fordiuretics,1.49
(1.40to1.59)forβblockers,1.25(1.17to1.33)forangiotensin
converting enzyme inhibitors, and 1.31 (1.17 to 1.47) for
non-losartan angiotensin II receptor blockers.
The direction and magnitude of associations with common
combination therapy were consistent with those from options
for monotherapy. In commonly used dual therapy options that
included diuretics, the multivariate relative risks for incident
gout compared with no use of antihypertensives were larger
with angiotensin converting enzyme inhibitors (3.17, 2.90 to
3.47)andwithβblockers(3.33,3.03to3.66)thanwithcalcium
channel blockers (2.11, 1.87 to 2.38). Similarly, in combined
use of β blockers, the corresponding relative risk with
angiotensin converting enzyme inhibitors (1.70, 1.48 to 1.96)
tended to be larger than that with calcium channel blockers
(1.24,1.07to1.96),whereastherelativeriskforthecombination
ofangiotensinconvertingenzymeinhibitorsandcalciumchannel
blockers was not significant (1.13, 0.96 to 1.32). Similarly, in
triple combination therapy options that included both diuretics
and angiotensin converting enzyme inhibitors, the multivariate
relativerisksforincidentgoutwerelargerwithβblockers(3.88,
3.43 to 4.38) than with calcium channel blockers (2.30, 2.01 to
2.63). Notably, the multivariate relative risk for the combined
use of calcium channel blockers and losartan was 0.66 (0.39 to
1.13), but the frequency of combined use was low (<1%).
Discussion
In this large general practice cohort representative of the UK
population, we found that use of calcium channel blockers and
losartanwasassociatedwithamoderatelylowerriskofincident
goutamongpatientswithhypertension.Theseassociationswere
independent of use of other evaluated antihypertensive drugs
and other risk factors for gout such as age, body mass index,
smoking, alcohol use, and presence of ischaemic heart disease,
hyperlipidaemia,hypertension,andrenalfailure.Theseinverse
associations were stronger with both a longer duration and a
higher dose of use. In contrast, we found that use of diuretics,
β blockers, angiotensin converting enzyme inhibitors, and
non-losartan angiotensin II receptor blockers was associated
with an increased risk of incident gout among patients with
hypertension. The magnitude of relative risk was strong with
diuretic use and more moderate with the other antihypertensive
drugs.Theseassociationswerealsoindependentofuseofother
antihypertensives and other risk factors for gout and tended to
becomestrongerwithalongerdurationofuseandahigherdose.
The absolute risk difference was the largest with diuretic use
(aboutsixcasesper1000personyears)andmoremoderatewith
the other agents (one or two cases per 1000 person years). The
current study provides the first large scale evidence for the
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against the risk for gout.
Theinverseassociationbetweenuseofcalciumchannelblockers
and risk of incident gout possibly stems from its action on renal
function. An increase in uric acid excretion has been observed
with calcium channel blockers.
11-13 Calcium channel blockers
could increase the glomerular filtration rate and consequently
the clearance rates of uric acid and creatinine. For example,
amlodipine has been found to increase the output of fluid from
the proximal tubules, as shown by the significant decrease
observed in the fractional proximal reabsorption of sodium and
the corresponding increase in the reabsorption of sodium in the
distal tubule
11 Furthermore, nifedipine, which possesses renal
vasodilatory effects,
23 has been found to reduce serum uric acid
levelscomparedwithaplacebointheACoronaryDiseaseTrial
Investigating Outcome with Nifedipine GITS (ACTION) trial
(n=7665).
10 Our data indicate that these amlodipine and
nifedipine effects on serum uric acid levels can be translated
into 21% and 13% decreased risks of gout, respectively, and a
similar protective association can be expected from diltiazem
as well.
Losartanreducesserumuricacidlevelsby20-25%byproducing
a uricosuric effect in healthy volunteers, patients with
hypertension,andtransplantrecipients.
12 13 15 16 24-26Theuricosuric
effect of losartan has been described to be similar to that
observed with classic uricosuric agents such as probenecid.
12 13
However,thisuricosuricmechanismdoesnotseemtoberelated
toangiotensinIIantagonism,asotherangiotensinIIantagonists
do not share the property. For example, other angiotensin II
antagonists, including valsartan 80 mg once daily,
27-30
candesartan 8-16 mg daily,
31 telmisartan
32 irbesartan,
24 33 and
eprosartan 600 mg
34-36 do not increase uricosuria and thus do
not decrease serum uric acid levels.
8 Similarly, angiotensin
converting enzyme inhibitors have not been associated with
lower serum uric levels.
16 Several experiments, including a
Xenopus oocyte model of urate transport injected with
URAT1-encoding RNA,
37 have indicated that losartan can
directly inhibit URAT1 from the apical side of tubular cells
throughcis-inhibitionaswithotheruricosuriccompoundssuch
as probenecid and benzbromarone.
3 37 38 These data suggest that
URAT1 could be the key action site of losartan, as with other
uricosuric agents.
We found that other antihypertensive drugs were associated
with an increased risk of incident gout. Diuretics increase the
net reabsorption of uric acid in the proximal tubule of the
nephron and thereby reduce urinary excretion and increase the
risk of hyperuricaemia
7 8 and gout.
2 The increase in serum uric
acid concentration and the risk of gout caused by diuretics may
benotedwithinafewdaysofthestartoftreatment.
39 40Although
not as impressive as the hyperuricaemic property of diuretics,
βblockers,includingpropranolol,atenolol,metoprolol,timolol,
and alprenolol, also have been shown to increase serum uric
acid levels.
8 9 For example, atenolol 50-100 mg daily for 12
weeksincreaseduricacidlevelsby0.5mg/dL
41andtheaddition
of propranolol was associated with a 0.3 mg/dL increase of
serum uric acid levels.
42 The mechanism of these urate raising
effectsofβblockersremainsunknownasthedataontheeffects
of β blockers on renal urate excretion have been unclear. For
example, whereas single doses of atenolol, propranolol, and
tertatolol did not modify the renal clearance of uric acid or the
24 hour urinary excretion of uric acid in healthy people,
42
propranolol was found to reduce the mean renal clearance of
uric acid in patients with hypertension.
43
Clinical and public health implications
Ourfindingsmayhavepracticalimplicationsinthemanagement
of hypertension, particularly among those who are at a higher
risk of developing gout. Our data suggest that calcium channel
blockersorlosartanwouldbepreferredtootherantihypertensive
drugs if prevention of gout is relevant and other determining
factors are comparable. Furthermore, from a public health
perspective, using these urate lowering antihypertensive drugs
could help reduce the high comorbidity burden of gout and
hypertension.
1 As our findings are based on the reference point
of no use of each corresponding antihypertensive drug, the
difference in risk of gout between urate lowering agents (for
example, losartan) compared with urate raising agents (for
example, thiazide) would be even greater, which could in turn
leadtonoteworthydifferencesinrisk-benefitratios,particularly
in populations at high risk for gout.
Strengths and limitations of the study
This study was carried out using a large UK general practice
population; therefore, findings are likely to be applicable to the
generalpopulation.Asantihypertensivedrugsareusedforother
clinical conditions, the overall consistency of the results
stratified by hypertension helped to sort out potential drug
effects from those of the underlying conditions. Because the
definition of gout was based on doctors’ diagnoses, a certain
level of misclassification of use is inevitable. A diagnosis of
gout could often have been recorded based on the suggestive
clinical presentation of gout without documentation of
monosodium urate crystals. However, any non-differential
misclassificationofthesediagnoseswouldhavebiasedthestudy
results toward the null and would not explain the strong
associationsanddose-responserelationsobservedinthisstudy.
Furthermore, when we used doctors’ diagnoses of gout
combined with anti-gout drug use (which showed a validity of
90%
21 22) as our case definition, our results remained almost
identical. Despite the large size of the study cohort, the number
of participants in certain subgroups (for example, use of
angiotensin II receptor blockers in the group without
hypertension or various combination therapy options) was
relatively small, which limited our ability to obtain robust
estimates. Replicating these results in the context of a larger
prospective cohort would be valuable. Such a larger study
context would also be useful for quantifying the effects of
switching antihypertensive drugs.
Conclusions
Ourfindingssuggestthatcalciumchannelblockersandlosartan
may be protective against the risk of gout among people with
hypertension.Thesedataarecompatiblewithpreviousfindings
that suggested these drugs have urate lowering properties. In
contrast, diuretics, β blockers, angiotensin converting enzyme
inhibitors,andnon-losartanangiotensinIIreceptorblockersare
associated with an increased risk of gout. These data may have
practical implications for choosing the appropriate
antihypertensivedrugsinpatientswithhypertension,acommon
comorbidity of gout.
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Hypertension is a common comorbidity of gout, affecting up to 74% of patients with gout
Unlike other antihypertensives, calcium channel blockers and losartan may reduce the risk of gout by lowering urate acid levels
No study has, however, investigated this potential link
What this study adds
Compatible with their urate lowering properties, calcium channel blockers and losartan are associated with a lower risk of incident gout
among people with hypertension
By contrast, diuretics, β blockers, angiotensin converting enzyme inhibitors, and non-losartan angiotensin II receptor blockers are
associated with an increased risk of gout
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Table 1| Characteristics of cases of gout and frequency matched controls stratified by presence of hypertension
No hypertension Hypertension
Variables
Relative risk* (95%
CI)
No (%) of cases
(n=11 910)
No (%) of controls
(n=33 720)
Relative risk* (95%
CI)
No (%) of cases
(n=12 858)
No (%) of controls
(n=16 280)
— 9515 (79.89) 26 055 (77.27) — 8431 (65.57) 10 898 (66.94) Men
— 2395 (20.11) 7665 (22.73) — 4427 (34.43) 5382 (33.06) Women
Age (years):
— 4130 (34.68) 9199 (27.28) — 1160 (9.02) 1012 (6.22) 20-49
— 2671 (22.43) 7745 (22.97) — 2202 (17.13) 2366 (14.53) 50-59
— 2330 (19.56) 7520 (22.30) — 3423 (26.62) 4410 (27.09) 60-69
— 1794 (15.06) 6268 (18.59) — 4064 (31.61) 5628 (34.57) 70-79
— 985 (8.27) 2988 (8.86) — 2009 (15.62) 2864 (17.59) 80-89
No of visits to
general practitioner:
1 4963 (41.67) 18 957 (56.22) 1 1822 (14.17) 3743 (22.99) 0-4
1.59 (1.51 to 1.68) 3278 (27.52) 8244 (24.45) 1.33 (1.23 to 1.43) 3414 (26.55) 4957 (30.45) 5-9
2.08 (1.95 to 2.21) 2489 (20.90) 4997 (14.82) 1.70 (1.58 to 1.82) 4911 (38.19) 5425 (33.32) 10-19
3.26 (2.99 to 3.56) 1180 (9.91) 1522 (4.51) 2.31 (2.12 to 2.51) 2711 (21.08) 2155 (13.24) ≥20
Smoking:
1 5484 (46.05) 15 793 (46.84) 1 6074 (47.24) 8239 (50.61) Non-smoker
0.82 (0.77 to 0.87) 2266 (19.03) 7431 (22.04) 0.78 (0.73 to 0.84) 1516 (11.79) 2500 (15.36) Current smoker
1.24 (1.17 to 1.31) 3050 (25.61) 6000 (17.79) 1.16 (1.10 to 1.22) 4901 (38.12) 4879 (29.97) Former smoker
0.90 (0.83 to 0.97) 1110 (9.32) 4496 (13.33) 1.06 (0.92 to 1.22) 367 (2.85) 662 (4.07) Unknown
Alcohol intake
(units/wk)†:
1 3035 (25.48) 9939 (29.48) 1 4593 (35.72) 6457 (39.66) Non-use
0.99 (0.94 to 1.06) 2589 (21.74) 8750 (25.95) 1.09 (1.02 to 1.15) 3371 (26.22) 4612 (28.33) 1-9
1.54 (1.44 to 1.65) 2530 (21.24) 5557 (16.48) 1.49 (1.39 to 1.60) 2544 (19.79) 2593 (15.93) 10-24
2.66 (2.42 to 2.93) 1090 (9.15) 1401 (4.15) 1.91 (1.72 to 2.14) 963 (7.49) 751 (4.61) 25-42
3.26 (2.81 to 3.77) 441 (3.70) 432 (1.28) 2.15 (1.78 to 2.61) 298 (2.32) 201 (1.23) ≥42
1.16 (1.09 to 1.24) 2225 (18.68) 7641 (22.66) 1.15 (1.05 to 1.25) 1089 (8.47) 1666 (10.23) Unknown
Body mass index:
0.67 (0.57 to 0.79) 192 (1.61) 1209 (3.59) 0.61 (0.49 to 0.76) 123 (0.96) 379 (2.33) <20
1 2262 (18.99) 9909 (29.39) 1 1963 (15.27) 3990 (24.51) 20-24.9
1.76 (1.66 to 1.87) 4214 (35.38) 10 265 (30.44) 1.55 (1.45 to 1.66) 4955 (38.54) 6358 (39.05) 25-29.9
2.71 (2.52 to 2.90) 2616 (21.96) 3710 (11.00) 2.19 (2.04 to 2.36) 4560 (35.46) 3702 (22.74) ≥30
1.49 (1.39 to 1.59) 2626 (22.05) 8627 (25.58) 1.56 (1.42 to 1.71) 1257 (9.78) 1851 (11.37) Unknown
Medical conditions:
1.54 (1.43 to 1.66) 1634 (13.72) 3046 (9.03) 1.19 (1.12 to 1.26) 3289 (25.58) 3670 (22.54) Ischaemic heart
disease
1.29 (1.20 to 1.39) 1274 (10.70) 2537 (7.52) 1.14 (1.08 to 1.21) 3305 (25.70) 3391 (20.83) Hyperlipidaemia
3.78 (3.00 to 4.76) 220 (1.85) 129 (0.38) 2.32 (2.03 to 2.66) 727 (5.65) 338 (2.08) Renal failure
4.06 (3.60 to 4.58) 794 (6.67) 614 (1.82) 2.32 (2.11 to 2.56) 1348 (10.48) 808 (4.96) Heart failure
*Adjusted for sex, age, calendar year, and visits to general practitioner.
†1 unit=10 ml of pure ethanol (8 g of alcohol).
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P for
interaction
No hypertension Hypertension
Use of
antihypertensives
Adjusted relative
risk* (95% CI)
No (%) of cases
(n=11 910)
No (%) of
controls (n=33
720)
Adjusted relative
risk* (95% CI)
No (%) of cases
(n=12 858)
No (%) of
controls (n=16
280)
Diuretics:
0.03 1 9445 (79.30) 30 161 (89.45) 1 2761 (21.47) 6076 (37.32) Never
3.01 (2.72 to 3.33) 1762 (14.79) 1728 (5.12) 2.36 (2.21 to 2.52) 8159 (63.45) 6854 (42.10) Current (<31 days)
1.65 (1.38 to 1.97) 244 (2.05) 461 (1.37) 1.57 (1.40 to 1.76) 806 (6.27) 1001 (6.15) Recent (31-365 days)
1.05 (0.93 to 1.18) 459 (3.85) 1370 (4.06) 0.98 (0.90 to 1.08) 1132 (8.80) 2349 (14.43) Past (>365 days)
β blockers:
0.04 1 9933 (83.40) 29 711 (88.11) 1 5079 (39.50) 8089 (49.69) Never
1.16 (1.04 to 1.29) 962 (8.08) 1620 (4.80) 1.48 (1.40 to 1.57) 4967 (38.63) 4749 (29.17) Current (<31 days)
1.12 (0.93 to 1.36) 204 (1.71) 405 (1.20) 1.20 (1.06 to 1.36) 625 (4.86) 671 (4.12) Recent (31-365 days)
0.97 (0.88 to 1.06) 811 (6.81) 1984 (5.88) 1.03 (0.96 to 1.11) 2187 (17.01) 2771 (17.02) Past (>365 days)
Calcium channel
blockers:
0.17 1 10 951 (91.95) 31 768 (94.21) 1 6685 (51.99) 9127 (56.06) Never
0.84 (0.73 to 0.97) 447 (3.75) 997 (2.96) 0.87 (0.82 to 0.93) 3388 (26.35) 4603 (28.27) Current (<31 days)
0.72 (0.55 to 0.96) 95 (0.80) 194 (0.58) 1.03 (0.91 to 1.17) 670 (5.21) 651 (4.00) Recent (31-365 days)
0.96 (0.82 to 1.11) 417 (3.50) 761 (2.26) 1.13 (1.04 to 1.23) 2115 (16.45) 1899 (11.66) Past (>365 days)
Angiotensin converting
enzyme inhibitors:
0.04 1 10 412 (87.42) 32 103 (95.20) 1 5630 (43.79) 9238 (56.74) Never
1.37 (1.21 to 1.54) 1085 (9.11) 1136 (3.37) 1.24 (1.17 to 1.32) 4818 (37.47) 4733 (29.07) Current (<31 days)
1.36 (1.05 to 1.77) 144 (1.21) 162 (0.48) 1.32 (1.16 to 1.50) 709 (5.51) 598 (3.67) Recent (31-365 days)
1.11 (0.90 to 1.38) 269 (2.26) 319 (0.95) 1.08 (0.99 to 1.19) 1701 (13.23) 1711 (10.51) Past (>365 days)
Losartan:
0.20 1 11 797 (99.05) 33 596 (99.63) 1 12 141 (94.42) 15 551 (95.52) Never
0.90 (0.62 to 1.30) 72 (0.60) 92 (0.27) 0.81 (0.70 to 0.94) 397 (3.09) 482 (2.96) Current (<31 days)
0.51 (0.21 to 1.25) 11 (0.09) 16 (0.05) 0.96 (0.68 to 1.35) 83 (0.65) 77 (0.47) Recent (31-365 days)
1.74 (0.88 to 3.43) 30 (0.25) 16 (0.05) 1.10 (0.89 to 1.37) 237 (1.84) 170 (1.04) Past (>365 days)
Non-losartan
angiotensin II receptor
blockers:
0.72 1 11 728 (98.47) 33 581 (99.59) 1 11 270 (87.65) 15 073 (92.59) Never
1.40 (1.04 to 1.88) 145 (1.22) 108 (0.32) 1.29 (1.16 to 1.43) 1223 (9.51) 895 (5.50) Current (<31 days)
1.24 (0.55 to 2.80) 16 (0.13) 15 (0.04) 1.05 (0.81 to 1.35) 150 (1.17) 134 (0.82) Recent (31-365 days)
1.20 (0.56 to 2.58) 21 (0.18) 16 (0.05) 1.13 (0.91 to 1.41) 215 (1.67) 178 (1.09) Past (>365 days)
*Adjusted for sex, age, calendar year, number of visits to a general practitioner, body mass index, alcohol intake, ischaemic heart disease, hyperlipidaemia,
diabetes, chronic renal failure and heart failure, and simultaneously for the other antihypertensive drug classes.
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hypertension
No hypertension Hypertension
Duration of
antihypertensive use
Adjusted relative risk*
(95% CI)
No (%) of cases
(n=11 910)
No (%) of
controls (n=33
720)
Adjusted relative risk*
(95% CI)
No (%) of cases
(n=12 858)
No (%) of controls
(n=16 280)
Diuretics:
2.26 (1.94 to 2.62) 436 (3.66) 570 (1.69) 1.79 (1.63 to 1.96) 1566 (12.18) 1751 (10.76) <1 year
2.77 (2.28 to 3.35) 290 (2.43) 309 (0.92) 2.27 (2.05 to 2.51) 1295 (10.07) 1160 (7.13) 1-1.9 years
3.63 (3.20 to 4.12) 1036 (8.70) 849 (2.52) 2.62 (2.44 to 2.82) 5298 (41.20) 3943 (24.22) ≥2 years
<0.001 <0.001 P for trend
β blockers:
1.10 (0.93 to 1.32) 262 (2.20) 503 (1.49) 1.36 (1.21 to 1.51) 861 (6.70) 933 (5.73) <1 year
1.23 (0.98 to 1.54) 188 (1.58) 264 (0.78) 1.52 (1.35 to 1.72) 732 (5.69) 691 (4.24) 1-1.9 years
1.18 (1.03 to 1.35) 512 (4.30) 853 (2.53) 1.47 (1.38 to 1.57) 3374 (26.24) 3125 (19.20) ≥2 years
0.24 0.15 P for trend
Calcium channel
blockers:
0.81 (0.63 to 1.04) 116 (0.97) 269 (0.80) 1.04 (0.94 to 1.15) 1004 (7.81) 1180 (7.25) <1 year
0.92 (0.68 to 1.27) 79 (0.66) 156 (0.46) 0.89 (0.78 to 1.00) 549 (4.27) 737 (4.53) 1-1.9 years
0.80 (0.67 to 0.96) 252 (2.12) 572 (1.70) 0.77 (0.71 to 0.83) 1835 (14.27) 2686 (16.50) ≥2 years
0.87 <0.001 P for trend
Angiotensin converting
enzyme inhibitors:
1.27 (1.05 to 1.53) 276 (2.32) 360 (1.07) 1.09 (0.99 to 1.20) 1058 (8.23) 1198 (7.36) <1 year
1.38 (1.09 to 1.74) 190 (1.60) 219 (0.65) 1.08 (0.96 to 1.22) 719 (5.59) 801 (4.92) 1-1.9 years
1.40 (1.20 to 1.63) 619 (5.20) 557 (1.65) 1.32 (1.23 to 1.42) 3041 (23.65) 2734 (16.79) ≥2 years
0.71 <0.001 P for trend
Losartan:
0.71 (0.35 to 1.45) 15 (0.13) 25 (0.07) 0.97 (0.74 to 1.27) 117 (0.91) 127 (0.78) <1 year
1.04 (0.49 to 2.22) 14 (0.12) 22 (0.07) 0.86 (0.62 to 1.18) 80 (0.62) 96 (0.59) 1-1.9 years
0.84 (0.52 to 1.37) 43 (0.36) 45 (0.13) 0.70 (0.57 to 0.86) 200 (1.56) 259 (1.59) ≥2 years
0.185 0.02 P for trend
Non-losartan
angiotensin II receptor
blockers:
1.54 (1.00 to 2.35) 66 (0.55) 46 (0.14) 1.20 (1.02 to 1.42) 381 (2.96) 316 (1.94) <1 year
1.30 (0.73 to 2.32) 33 (0.28) 26 (0.08) 1.30 (1.06 to 1.59) 275 (2.14) 203 (1.25) 1-1.9 years
1.12 (0.68 to 1.86) 46 (0.39) 36 (0.11) 1.33 (1.14 to 1.54) 567 (4.41) 376 (2.31) ≥2 years
0.12 0.67 P for trend
*Adjusted for sex, age, calendar year, number of visits to general practitioner, body mass index, alcohol intake, ischaemic heart disease, hyperlipidaemia, diabetes,
chronic renal failure, heart failure, and simultaneously for the other antihypertensive drug classes.
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hypertension
No hypertension Hypertension
Daily dose
Adjusted relative risk*
(95% CI)
No (%) of cases (n=11
910)
No (%) of controls
(n=33 720)
Adjusted relative
risk* (95% CI)
No (%) of
cases (n=12
858)
No (%) of
controls (n=16
280)
Diuretics:
2.72 (2.44 to 3.03) 1249 (10.49) 1361 (4.04) 2.24 (2.09 to 2.39) 6320 (49.15) 5630 (34.58) Low or medium
dose
4.16 (3.45 to 5.02) 419 (3.52) 263 (0.78) 2.99 (2.63 to 3.40) 971 (7.55) 579 (3.56) High dose
3.60 (2.63 to 4.92) 94 (0.79) 104 (0.31) 2.76 (2.43 to 3.12) 868 (6.75) 645 (3.96) Unknown
β blockers:
1.15 (1.02 to 1.29) 697 (5.85) 1258 (3.73) 1.39 (1.30 to 1.49) 3156 (24.55) 3234 (19.86) Low or medium
dose
1.14 (0.94 to 1.39) 237 (1.99) 319 (0.95) 1.59 (1.46 to 1.74) 1677 (13.04) 1377 (8.46) High dose
1.69 (0.99 to 2.90) 28 (0.24) 43 (0.13) 1.63 (1.25 to 2.13) 134 (1.04) 138 (0.85) Unknown
Calcium channel
blockers:
0.83 (0.70 to 0.99) 272 (2.28) 626 (1.86) 0.90 (0.84 to 0.98) 1757 (13.66) 2298 (14.12) Low or medium
dose
0.84 (0.67 to 1.04) 170 (1.43) 359 (1.06) 0.80 (0.74 to 0.87) 1596 (12.41) 2271 (13.95) High dose
1.26 (0.36 to 4.38) 5 (0.04) 12 (0.04) 1.80 (1.07 to 3.04) 35 (0.27) 34 (0.21) Unknown
Angiotensin
converting enzyme
inhibitors:
1.33 (1.15 to 1.54) 538 (4.52) 657 (1.95) 1.23 (1.14 to 1.33) 1848 (14.37) 1998 (12.27) Low or medium
dose
1.39 (1.18 to 1.63) 532 (4.47) 465 (1.38) 1.23 (1.15 to 1.33) 2914 (22.66) 2665 (16.37) High dose
1.84 (0.81 to 4.21) 15 (0.13) 14 (0.04) 0.96 (0.65 to 1.41) 56 (0.44) 70 (0.43) Unknown
Losartan:
0.93 (0.63 to 1.39) 61 (0.51) 77 (0.23) 0.88 (0.73 to 1.06) 245 (1.91) 287 (1.76) Low or medium
dose
0.52 (0.22 to 1.26) 10 (0.08) 15 (0.04) 0.66 (0.52 to 0.84) 149 (1.16) 190 (1.17) High dose
— 1 (0.01) 0 (0.00) 0.66 (0.15 to 2.89) 3 (0.02) 5 (0.03) Unknown
Non-losartan
angiotensin II
receptor blockers:
1.24 (0.90 to 1.72) 112 (0.94) 89 (0.26) 1.20 (1.06 to 1.36) 712 (5.54) 582 (3.57) Low or medium
dose
1.89 (0.98 to 3.61) 32 (0.27) 18 (0.05) 1.40 (1.19 to 1.65) 486 (3.78) 298 (1.83) High dose
0.85 (0.03 to 24.19) 1 (0.01) 1 (0.01) 1.14 (0.58 to 2.25) 25 (0.19) 15 (0.09) Unknown
*Adjusted for sex, age, calendar year, number of visits to general practitioner, body mass index, alcohol intake, ischaemic heart disease, hyperlipidaemia, diabetes,
chronic renal failure, heart failure, and simultaneously for the other antihypertensive drug classes.
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